Autologous Whole Blood Management for Postoperative Hemorrhage

Waitlist Available
Led By Angela R Neufeld, MD
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult (≥18 yr)
Surgical patients at the Mazankowski Alberta Heart Institute
Must not have
Be younger than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up12 months
Awards & highlights
No Placebo-Only Group

Study Summary

This trial will test a protocol to see if using a patient's own blood is as good as donated blood products to reduce blood loss in heart surgery.

Eligible Conditions
  • Postoperative Hemorrhage
  • Anemia

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adequacy of recruitment.
Secondary outcome measures
24-Hour chest tube output.
Dose of fibrinogen.
Dose of prothrombin complex concentrates.
+12 more
Other outcome measures
Number of major protocol deviations (adherence).
Number of participants with inadvertent unblinding of the intensive care clinicians.
Number of participants without complete follow-up.
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Autologous Whole Blood ManagementExperimental Treatment1 Intervention
Intraoperative high volume autologous whole blood withdrawal prior to cardiopulmonary bypass (CPB) with re-transfusion following weaning from CPB.
Group II: Allogenic and Derivative TransfusionActive Control1 Intervention
Control arm participants will receive standard care involving transfusion of plasma, platelets, cryoprecipitate, and/or lyophilized concentrates following weaning from CPB.

Find a site

Who is running the clinical trial?

University of AlbertaLead Sponsor
864 Previous Clinical Trials
390,717 Total Patients Enrolled
University Hospital FoundationOTHER
7 Previous Clinical Trials
1,322 Total Patients Enrolled
Alberta Innovates Health SolutionsOTHER
51 Previous Clinical Trials
103,649 Total Patients Enrolled

Media Library

Autologous Whole Blood Management Clinical Trial Eligibility Overview. Trial Name: NCT05889494 — N/A
Postoperative Hemorrhage Research Study Groups: Autologous Whole Blood Management, Allogenic and Derivative Transfusion
Postoperative Hemorrhage Clinical Trial 2023: Autologous Whole Blood Management Highlights & Side Effects. Trial Name: NCT05889494 — N/A
Autologous Whole Blood Management 2023 Treatment Timeline for Medical Study. Trial Name: NCT05889494 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment restricted to seniors aged 85 or below for this experiment?

"This clinical trial has set the lower age limit at 18 and established an upper bound of 85, in compliance with its inclusion criteria."

Answered by AI

Could I be accepted as a participant in this research?

"To be eligible for this medical trial, a patient must have postoperative bleeding and lie between 18 to 85 years of age. Currently, 64 individuals are being actively recruited."

Answered by AI

Is the enrollment window still open for this research project?

"Per the site, this research is not currently recruiting volunteers as of May 25th 2023. Although there are no available positions in this trial, 363 other trials hosted on the same platform are actively searching for participants."

Answered by AI
~43 spots leftby Jun 2024